Compare SABR & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABR | ZVRA |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.0M | 472.9M |
| IPO Year | 2014 | 2015 |
| Metric | SABR | ZVRA |
|---|---|---|
| Price | $1.66 | $10.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $3.70 | ★ $21.71 |
| AVG Volume (30 Days) | ★ 17.4M | 859.4K |
| Earning Date | 05-21-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 283.56 | 159.21 |
| EPS | 1.34 | ★ 1.35 |
| Revenue | ★ $3,866,956,000.00 | $106,470,000.00 |
| Revenue This Year | $7.40 | $333.64 |
| Revenue Next Year | $3.26 | $44.19 |
| P/E Ratio | ★ $1.24 | $7.71 |
| Revenue Growth | 7.46 | ★ 350.91 |
| 52 Week Low | $0.81 | $6.19 |
| 52 Week High | $3.63 | $13.16 |
| Indicator | SABR | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 65.40 |
| Support Level | $1.63 | $8.31 |
| Resistance Level | $1.70 | $12.14 |
| Average True Range (ATR) | 0.20 | 0.43 |
| MACD | 0.06 | 0.17 |
| Stochastic Oscillator | 71.43 | 66.79 |
Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.